Enlivex Becomes World’s First Publicly Traded Company to Adopt a RAIN Prediction Markets Token Digital Asset Treasury Strategy
MIAMI – Dec. 3, 2025 – Global law firm Greenberg Traurig, LLP advised Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, in connection with its $212 million private placement.
The transaction, which closed Nov. 24, included the purchase and sale of 212 million ordinary shares (or equivalents in lieu thereof) of Enlivex at $1 per share. The net proceeds will support Enlivex’s adoption of a prediction markets digital asset treasury strategy through RAIN token accumulation, according to the company’s press release.
RAIN is a decentralized protocol for prediction markets and options trading built on the Arbitrum network. Enlivex plans to leverage blockchain technology and the growing trend of prediction-driven models, while continuing to focus on core business operations that include the development of Allocetra™, a therapy for the treatment of knee osteoarthritis.
“Enlivex Therapeutics is a longtime Greenberg Traurig client and we’re pleased to have assisted the company in this transaction,” said Robert L. Grossman, Corporate Practice shareholder based in Miami and past chair of the firm’s Israel practice. “The team was spearheaded by Drew M. Altman, co-chair of our Miami Corporate Practice, along with Win Rutherfurd, Boston Corporate shareholder. The team also includes Tampa Corporate Associate Chase Wathen, Miami Corporate Associates Meryl Roux Jimenez and Jeannie B. Regidor, and Law Clerk Angel Marcial.”